MiR-26a-1 Promotes DNA Damage Repair by Inhibiting Sirt1 and KDM5A in Human Liver Cancer Stem Cells

Liyan Wang
Tongji University

Xiaonan Li
Tongji University

Rushi Qin
Tongji University

Yanan Lu
Tongji University

shuting Song
Tongji University

Yingjie Chen
Tongji University

Sijie Xie
Tongji University

Xiaoxue Jiang
Tongji University

Dongdong Lu (✉ ludongdong@tongji.edu.cn)
Tongji University

https://orcid.org/0000-0002-7417-4172

Research

Keywords: MiR-26a-1, DNA damage repair, Sirt1, KDM5A, liver cancer stem cells

DOI: https://doi.org/10.21203/rs.3.rs-251571/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** Although miR-26a-1 was down-regulated expression in several cancers, the role of miR-26a-1 in malignancies has yet to be systematically elucidated.

**Methods:** RT-PCR, Western blotting and tumorigenesis test in vitro and in vivo were performed to analyze the signaling pathway.

**Results:** miR-26a-1 inhibits the NAD(+) dependent deacetylase Sirt1 expression by targeting the 3’ non-coding region of Sirt1 which enhances the acetylation modification of H4 on the 16th lysine of histone and the expression of protein arginine methyltransferase PRMT6. Therefore, miR-26a-1 promotes arginine methylation modification of POLB (R137) and histone. On the other hand, miR-26a-1 inhibits the expression of KDM5A by targeting its 3’ non-coding region, which enhances the methylation modification of histone H3 lysine 4. Moreover, miR-26a-1 enhances the expression of histone methyltransferase SETD2 dependent on H3K4me3 and further increases the trimethylation modification of the histone H3 lysine 36. Significantly, miR-26a-1 promotes the formation of DNA damage repair complex (Rad51-PARP1-ATR-ATM-hMSH6-XRCC-POLB-SKP2) via H3K36me3. In particular, it was found that miR-26a-1 inhibited the function of long non-coding RNA HULC and promoted the formation of DNA damage repair complex. Furthermore, miR-26a-1 promotes the DNA damage repair ability by promoting the DNA damage repair complex to bind to the DNA damage site, thereby inhibiting the DNA damage of liver cancer stem cells. In particular, miR-26a-1 enhanced the binding of H3F3A to Skp2, CUL1, and F-box at the DNA damage site and enhanced the protein ubiquitination modification of H3F3A, which promoted Histone H3 replaces H3F3A by degrading H3F3A, realizing the renewal of histones after DNA damage repair. It was further found that miR-26a-1 inhibited the formation and instability of DNA microsatellites by promoting DNA damage repair, thereby affecting the expression of several cyclins and protein kinases in liver cancer stem cells, such as, inhibiting CDK2 and CyclinE, CDK4, CyclinD1, CDK6, CDK8, CyclinM2, CDK15, pRB, PCNA, MAP3K2, PGK1 and promoting RB, P18, P21/WAF1/Cip1, and thus inhibited the growth of liver cancer stem cells. Strikingly, the rescued-test further confirmed that excessive Sirt1 and KDM5A abrogated the oncogenic function of miR-26a-1. Conclusions: miR26a-1 may acts as the potential biomarker and therapeutic target for liver cancer.

**Background**

Although miR-26a-1 was down-regulated expression in several cancers, the role of miR-26a-1 in malignancies has yet to be systematically elucidated. miR-26 suppresses adipocyte progenitor differentiation and fat production by targeting Fbxl19 and miR-26 blocks adipogenesis, at least in part, by repressing expression of Fbxl19 (1). RNA G-quadruplexes (RG4s) appears to be important in post-transcriptional gene regulation, highlighting an important role of RG4 in physiology and pathology (2). miR26a protected VSMCs against H2O2induced injury through activation of the PTEN/AKT/mTOR pathway, and miR26a may be considered as a potential prognostic biomarker and therapeutic target in the treatment of AAA injury through activation of the PTEN/AKT/mTOR pathway (3). knockout of miR26a
increased surfactant-associated mRNA and protein expression levels (4). In particular, Expression of miR26a exhibits a negative correlation with HMGA1 and regulates cancer progression by targeting HMGA1 in lung adenocarcinoma cells (5).

DNA damage repair plays an important role in hepatocarcinogenesis. The decision between cell survival and death following DNA damage rests on factors that are involved in DNA damage recognition, as well as on factors involved in the activation of apoptosis, autophagy (6). Deviations in this fine-tuning are known to destabilize cellular metabolic homeostasis, as exemplified in diverse cancers where disruption or deregulation of DNA repair pathways results in genome instability (7). DNA repair factors ultimately contribute to DNA repair pathway choice between homologous recombination and non-homologous end joining (8). Cancer chemotherapy and radiotherapy are designed to kill cancer cells mostly by inducing DNA damage. (9). DNA damage repair systems have evolved to act as a genome-wide surveillance mechanism to maintain chromosome integrity and impairment of these systems gives rise to mutations and directly contributes to tumorigenesis (10).

In the study, miR-26a-1 inhibits the expression of NAD+-dependent deacetylase Sirt1 and KDM5A, thereafter, miR-26a-1 promotes DNA damage repair, thereby affecting the expression of some cyclins and protein kinases in liver cancer stem cells. Moreover, excessive Sirt1 and KDM5A abolished the oncogenic functions of miR-26a-1 in liver cancer stem cells. In conclusions, miR26a-1 may acts as the potential biomarker and therapeutic target for liver cancer. We also shed light on the fact that the attenuation of deregulated functioning of miRNA could be a viable approach for cancer treatment.

**Materials And Methods**

**CD133+/CD44+ Huh7 cells sorting** CD133/CD44 MicroBead Kits were purchased from Miltenyi technic (Boston, USA) and MACS® Technology operation according to and the operation according to the manufacturer.

**Cell Lines** Cells were maintained in Dulbecco's modified Eagle medium (Gibco BRL Life Technologies) supplemented with 10% heat-inactivated (56°C, 30 minutes) fetal bovine serum (sigma) in a humidified atmosphere of 5% CO2 incubator at 37°C.

**RT-PCR** cDNA was prepared by using oligonucleotide (dT), random primers, and a SuperScript First-Strand Synthesis System (Invitrogen). PCR analysis was performed according to the manufacturer. β-actin was used as an internal control.

**Western Blotting** Proteins were separated on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a nitrocellulose membranes (Invitrogen). And then blocked in 10% dry milk-TBST (20mM Tris-HCl [PH 7.6], 127mM NaCl, 0.1% Tween 20) for 1 h at 37°C. Following three washes in Tris-HCl pH 7.5 with 0.1% Tween 20, the blots were incubated with antibody(appropriate dilution) overnight at 4°C. Signals were visualized by enhanced chemiluminescence plus kit(GE Healthcare).
RNA Immunoprecipitation (RIP) Ribonucleoprotein particle-enriched lysates were incubated with protein G/A-plus agarose beads (Santa Cruz) together with antibody or normal rabbit IgG for 4 hours at 4°C. Beads were subsequently washed. RNAs were isolated and then RT-PCR.

Super-RNA-EMSA Cells were washed and scraped in ice-cold PBS to prepare nuclei for electrophoretic gel mobility shift assay with the use of the gel shift assay system (Promega) modified according to the manufacturer’s instructions.

CHIP assay Cells were cross-linked with 1% (v/v) formaldehyde (Sigma) for 10 min at room temperature and stopped with 125 mm glycine for 5 min. Crossed-linked cells were washed with phosphate-buffered saline, resuspended in lysis buffer, and sonicated for 8–10 min in a SONICS VibraCell to generate DNA fragments. Chromatin extracts were diluted 5-fold with dilution buffer, pre-cleared with Protein-A/G-Sepharose beads, and immunoprecipitated with specific antibody on Protein-A/G-Sepharose beads. After washing, elution and de-cross-linking, the ChIP DNA was detected by PCR.

DNA damage repair assay DNA damage marker rH2AX (S139) detection, in situ DNA damage analysis and Quantitative analysis of DNA Damage via 8-OHdG were performed according to the manufacturer’s instructions, respectively.

Cell colony-formation efficiency assay cells were plated in six wells and incubated in a humidified atmosphere of 5% CO$_2$ incubator at 37°C for 14 days. For visualization, colonies were stained with 0.5% Crystal Violet (sigma) in 50% methanol and 10% glacial acetic acid. Colonies were counted using a dissecting microscope by MacBiophotonics Image J.

Tumorigenesis test In vivo Four-weeks male athymic Balb/c mice were maintained in the Tongji university animal facilities approved by the China Association for accreditation of laboratory animal care. athymic Balb/c mice per group were injected at the armpit area subcutaneously with cells. The mice were observed over 4 weeks for tumor formation. The mice were then sacrificed and the tumors recovered. The wet weight of each tumor was determined for each mouse. A portion of each tumor was fixed in 4% paraformaldehyde and embedded in paraffin for histological examination.

Results

miR-26a-1 inhibits the growth of liver cancer stem cells

To investigate the effect of miR-26a-1 on human liver cancer stem cells, CD133/CD44/CD24/EpCAM microbeads (MicroBeads) were used to isolate liver cancer stem cells from the Huh7 cell line (Figure S1A). CD133, CD44, CD24 and EpCAM were expressed in hLCSCs cells (Figure S1B&C). Moreover, the sphere and xenograft tumor (0.657 ± 0.193 gram vs 0, n = 10, p = 0.00000067 < 0.01) are produced in hLCSCs group, but not in non-hLCSCs group(Figure S1D&E). In human hLCSCs transfected with rLV, rLV-miR-26a-1, rLV-Cas9, rLV-Cas9-miR-26a-1 (Fig. 1A), miR-26a-1 was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and knocked out in rLV-Cas9- miR-26a-1 group Compared with
the rLV-Cas9 group (Fig. 1B-F). The cell grow ability was significantly decreased in the rLV-miR-26a-1 group compared with the rLV group (24 hours: \( P = 0.0054 < 0.01 \); 48 hours: \( P = 0.00259 < 0.01 \)) and increased in rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (24th hour: \( P = 0.001533 < 0.01 \); 48 hours: \( P = 0.003099 < 0.01 \)) (Fig. 1G). The positive rate of BrdU was significantly decreased in the rLV-miR-26a-1 group compared with the rLV group (36.93 ± 4.33% vs 19.27 ± 2.19%, \( P = 0.0192 < 0.01 \)) and increased in rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (40.75 ± 4.26% vs 70.59 ± 7.96%, \( P = 0.0028909 < 0.01 \)) (Fig. 1H). The colony formation ability was significantly decreased in the rLV-miR-26a-1 group compared with the rLV group (42.34 ± 3.01% vs 11.15 ± 2%, \( P = 0.0003451 < 0.01 \)) and increased in rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (43.67 ± 3.85% vs 81.12 ± 7.28%, \( P = 0.00576 < 0.01 \)) (Fig. 1I). The sphere formation rate was significantly decreased in the rLV-miR-26a-1 group compared with the rLV-Cas9 group (59.64 ± 6.27% vs 23.89 ± 2.69%, \( P = 0.00793 < 0.01 \)) and increased in rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (64.82 ± 8.65% vs 64.82 ± 8.65%, \( P = 0.009971 < 0.01 \)) (Fig. 1J). The average weight of xenograft tumors was significantly decreased in the rLV-miR-26a-1 group compared with the rLV group (0.51 ± 0.065g vs 0.16 ± 0.0374g, \( P = 0.00000534 < 0.01 \)) and increased in rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (0.46 ± 0.0516 grams vs 0.9714 ± 0.2333 grams, \( P = 0.000579 < 0.01 \)) (Fig. 1K&L). The average appearance time of xenograft tumors was significantly increased in the rLV-Cas9-miR-26a-1 group compared with the rLV group (8.86 ± 0.69 days vs 14.86 ± 1.86 days, \( P = 0.0000232 < 0.01 \)) and decreased in rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (9.29 ± 1.112 days vs 6.143 ± 0.8997 days, \( P = < 0.01 \)) (Fig. 1M). The poorly differentiated cancer cells in transplanted tumor tissues was reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV group and increased in rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (1N). PCNA expression was reduced in the rLV-miR-26a-1 group compared with the rLV group (34.21 ± 9.403% vs 11.22 ± 2.86%, \( P = 0.000834 < 0.01 \)) and increased in rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (30.45 ± 3.48% vs 67.46 ± 5.09%, \( p = 0.000042048 < 0.01 \)) (Fig. 1Oa&b). Collectively, these results suggest that miR-26a-1 inhibits the growth of human liver cancer stem cells[Also see and Supplemental Results: miR-26a-1 inhibits the growth of human liver cancer stem cells (Figure S2A-O)].

**miR-26a-1 targets NAD+-dependent deacetylase Sirt1 and enhances the acetylation modification of histone H4 lysine 16**

To clarify the effect of miR-26a-1 on human liver cancer stem cell lines (hLCSCs), we will analyze whether miR-26a-1 targets NAD+-dependent deacetylase Sirt1 and enhances the acetylation modification of histone H4 lysine 16. miR-26a-1 was significantly increased in rLV–miR-26a-1 group compared with rLV group and decreased in rLV-Cas9–miR-26a-1 group compared with rLV-Cas9 group (Fig. 2A-D). Bioinformatics analysis showed that the mature sequence of miR-26a-1 was linked to Sirt1 mRNA 3’-noncoding region through 13 base complementary seed sequences (UTR) (1153–1159) (Fig. 2E). The pEZX-MT-Sirt1 3’-UTR-Luc luciferase reporter gene activity was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group (20029.1 ± 1136.69 vs 3781.82 ± 474.12, \( P = 0.0014437 < 0.01 \)) and was significantly increased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (21843.3 ± 1556.64 vs 38605.05 ± 4454.28, \( P = 0.006014 < 0.01 \)) (Fig. 2F). The pEZX-MT-Sirt1 3’-UTR (mutant)-Luc
luciferase reporter gene activity was not significantly changed in rLV-miR-26a-1 group compared with the rLV group (18573.59 ± 2743.32 vs 20258.26 ± 1196.50, P = 0.1948 > 0.05) and in rLV-Cas9-miR-26a-1 group compared with rLV-Cas9 group (20769.59 ± 2369.82 vs 19305.63 ± 1167.56, P = 0.273944 > 0.05) (Fig. 2G). Although the transcription level of Sirt1 was not significantly altered (Fig. 2H), the level of translation of Sitr1 was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group and increased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 2I). The level of H4K16Ac was significantly increased in the rLV-miR-26a-1 group compared with the rLV group increased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 2J). However, the level of H4K16Ac was not significantly altered in hLCSCs in the rLV-miR-26a-1 + rLV-Sirt1 group compared with the rLV group (Fig. 2K). Collectively, these results suggest that miR-26a-1 enhances the acetylation modification of histone H4 lysine 16 by reducing Sirt1 [Also see and Supplemental Results: miR-26a-1 targets NAD+-dependent deacetylase Sirt1 in human liver cancer stem cells and enhances the acetylation modification of histone H4 lysine 16 (FigureS3A-L)].

**miR-26a-1 enhances the expression of protein arginine methyltransferase PRMT6**

Given that miR-26a-1 increases the acetylation modification of histone H4 lysine 16, we will further investigate whether miR-26a-1 enhances protein PRMT6 in liver cancer stem cells. The loading of H4K16Ac with PRMT6 promoter was significantly enhanced in the rLV-miR-26a-1 group compared with the rLV group and weakened in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 3A). The binding ability of H4K16Ac with the PRMT6 promoter probe was significantly enhanced in the rLV-miR-26a-1 group compared with the rLV group and decreased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 3B). The ability of H4K16Ac and RNA PolIII to enter the PRMT6 promoter-enhancer loop was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and weakened in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 3C). However, the ability of H4K16Ac and RNA PolIII to enter the PRMT6 promoter-enhancer loop was not significantly changed in the rLV-miR-26a-1 + H4K16Ac inhibitor group compared with the rLV group (Fig. 3D). The activity of the pEZX-MT-PRMT6 promoter-Luc luciferase activity was significantly increased in the rLV-miR-26-1 group compared with the rLV group (77457.45 ± 10051.33 vs 270650.41 ± 41120.78, P = 0.005127 < 0.01) and reduced rLV-Cas9-miR-26a-1 group compared to rLV-Cas9 group (74895.04 ± 6114.57 vs 10770.04 ± 1695.32, P = < 0.000892510.01) (Fig. 3E). Although the pEZX-MT-PRMT6 promoter-Luc luciferase activity was significantly increased in the rLV-miR-26-1 group compared with the rLV group (59240.21 ± 9355.84 vs 167876.6 ± 11085.01, P = 0.0009681 < 0.01), however, it was not significantly altered in the rLV-miR-26a-1 + rLV-Sirt1 group compared with rLV group (59240.21 ± 9355.84 vs 51853.19 ± 3551.72, P = 0.11984 > 0.051) (Fig. 3F). The expression level of PRMT6 was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and decreased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 3G&H). However, the expression level of PRMT6 was not significantly altered in the rLV-miR-26a-1 + rLV-Sirt1 group compared with the rLV group (Fig. 3I&J). Collectively, these results suggest that miR-26a-1 enhances the expression of PRMT6 gene dependently on H4K16Ac [Also see and Supplemental Results: miR-26a-1 enhances the expression of protein arginine methyltransferase PRMT6(FigureS4A-J)].
miR-26a-1 promotes the methylation modification of POLB (R137) and histone arginine through PRMT6

Given that miR-26a-1 promotes the expression of PRMT6, we will analyze whether miR-26a-1 affects the methylation modification of POLB(R137) and histone arginine through PRMT6 in liver cancer stem cells. The expression of POLB was not significantly altered in the rLV-miR-26a-1 group compared with the rLV group and in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 4A). The interaction between POLB and PRMT6 was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and decreased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 4B). The level of methylation modification of POLB (R137) was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and decreased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 4C). However, the methylation modification level of PPOLB (R137) was not significantly changed in the hLCSCs of the rLV-miR-26a-1 + pGFP-V-RS-PRMT6 group compared with the rLV group (Fig. 4D). The interaction of H2A, H3, H4 with PRMT6 was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and decreased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 4E). The modification level of H3R2me2, H2AR3me, H4R3me was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and decreased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 4F). However, the H3R2me2, H2AR3me and H4R3me were not significantly changed in the rLV-miR-26a-1 + pGFP-V-RS-PRMT6 group compared with the rLV group (Fig. 4G). Collectively, these results suggest that miR-26a-1 enhances the methylation modification of POLB(R137) and histone arginine through PRMT6 [Also see and Supplemental Results: miR-26a-1 promotes the methylation modification of POLB (R137) and histone arginine through PRMT6(Figure S5A-G)].

miR-26a-1 enhances the methylation modification of histone H3 lysine 4 via targeting KDM5A

In order to study whether miR-26a-1 affects the expression of KDM5A and the methylation modification of histone H3 lysine 4, we conducted related experiments. The mature miR-26a-1 binds to KDM5A "mRNA" 3'-uncoding region (UTR) (4606–4612) through an 11-base complementary seed sequence(Fig. 5A). The pEZX-MT-KDM5A 3'-UTR-Luc luciferase reporter gene was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group (23493.59 ± 2166.57 vs 6301.64 ± 829.17, P = 0.00108 < 0.01) and enhanced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (30661.08 ± 2077.47 vs 88263.9 ± 9474.02, P = 0.003246 < 0.01) (Fig. 5B). The pEZX-MT-KDM5A 3'-UTR(mutant)-Luc luciferase reporter gene activity was not significantly altered in rLV-miR-26a-1 group compared with the rLV group (23493.59 ± 2166.57 vs 6301.64 ± 829.17, P = 0.00108 < 0.01) and enhanced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (30661.08 ± 2077.47 vs 88263.9 ± 9474.02, P = 0.003246 < 0.01) (Fig. 5B). The pEZX-MT-KDM5A 3'-UTR(mutant)-Luc luciferase reporter gene activity was significantly increased in rLV-miR-26a-1 group compared with the rLV group (31943.78 ± 3240.52 vs 31529.30 ± 1797.79, P = 0.437 > 0.05) and in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (34014.63 ± 2880.78 vs 34666.77 ± 4845.20, P = 0.415 > 0.05) (Fig. 5C). The transcription level of KDM5A was not significantly altered in rLV-miR-26a-1 group compared with the rLV group and in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 5D). The expression of KDM5A was significantly reduced in rLV-miR-26a-1 group compared with the rLV group and increased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 5E). The level of H3K4me3 was significantly increased in rLV-miR-26a-1 group compared with the rLV group and decreased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 5F). However, the
level of H3K4me3 was not significantly altered in the rLV-miR-26a-1 + rLV-KDM5A group compared with the rLV group (Fig. 5G). Collectively, these results suggest that miR-26a-1 enhances the methylation modification of histone H3 lysine 4 by reducing KDM5A [Also see and Supplemental Results: miR-26a-1 enhances the methylation modification of histone H3 lysine 4 via targeting KDM5A (FigureS6A-G)].

**miR-26a-1 enhances the expression of histone methyltransferase SETD2 and the trimethylation modification on the 36th lysine of Histone H3 dependent on H3K4me3**

Given that miR-26a-1 increases the trimethylation modification of histone H3 lysine 4, we will further investigate whether miR-26a-1 affects SETD2 and H3K36me3 dependent on H3K4me3. The binding ability of H3K4me3 to the histone methyltransferase SETD2 promoter was significantly enhanced in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 6A). The binding ability of H3K4me3 to the histone methyltransferase SETD2 promoter probe was significantly enhanced in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 6B). The ability of H3K4me3 and RNA PolII to enter the histone methyltransferase SETD2 promoter-enhancer loop was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 6C). However, it was not significantly altered in the rLV-miR-26a-1 + rLV-KDM5A group compared with the rLV group (Fig. 6D). The activity of the pEZX-MT-SETD2 promoter-Luc luciferase reporter gene was significantly increased in the rLV-miR-26a-1 group compared with the rLV group (316758.34 ± 45109.35 vs 1781523.14 ± 99201.06, P = 0.00044 < 0.01) and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (368253.56 ± 75472.56 vs 47702.19 ± 9066.13, P = 0.06122 > 0.051) (Fig. 6E). However, it was not significantly altered in the rLV-miR-26a-1 + rLV-KDM5A group compared with the rLV group (551892.38 ± 112067.76 vs 677012.65 ± 78394.74, P = 0.06122 > 0.051) (Fig. 6F). The expression of SETD2 was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 6G&H). However, it was not significantly altered (Fig. 6I&J). The interaction between histone H3 and SETD2 was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 6K). The H3K36me3 was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 6L). However, it was not significantly altered in the rLV-miR-26a-1 + pGFP-VRS-SETD2 group compared with the rLV group (Fig. 6M). Collectively, these results suggest that miR-26a-1 enhances the expression of histone methyltransferase SETD2 and the trimethylation modification on the 36th lysine of Histone H3 dependent on H3K4me3 [Also see and Supplemental Results: miR-26a-1 enhances the expression of histone methyltransferase SETD2 and the trimethylation modification on the 36th lysine of Histone H3 dependent on H3K4me3 (FigureS7A-O)].

**miR-26a-1 promotes the formation of DNA damage repair complex dependent on the H3K36me3**
Given that miR-26a-1 promotes the trimethylation of histone H3 on lysine 36, we will analyze whether miR-26a-1 to promote DNA damage repair complex formation dependent on the trimethylation of histone H3 on lysine 36. The binding ability of H3K36me3 with Rad51, PARP1, ATR, ATM, hMSH6, XRCC5, POLB, and SKP2 was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 7A). The binding of mismatched DNA damage probes to Rad51, PARP1, ATR, ATM, hMSH6, XRCC5, POLB, SKP2 was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 7B). However, the H3K36me3 was significantly reduced in the rLV-miR-26a-1 + rLV-KDM4A group compared with the rLV group (Fig. 7C). The binding ability of Rad51, PARP1, ATR, ATM, hMSH6, XRCC5, POLB, and SKP2 to mismatched DNA damage probes was not significantly altered in the rLV-miR-26a-1 + rLV-KDM4A group compared with the rLV group (Fig. 7D). Next, Transfect the mismatched plasmid was transfected (Fig. 7E) and then perform repeated chromatin immunoprecipitation (CHIP) to analyze the binding ability of the methylated POLB with the mismatched sequence. The results showed that the binding ability of the methylated POLB to the mismatched DNA sequence was significantly enhanced in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 7F). The binding ability of mismatched DNA sequences to Rad51, PARP1, ATR, ATM, hMSH6, XRCC5, POLB, SKP2 was significantly enhanced in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 7G). Collectively, these results suggest that miR-26a-1 enhances the binding ability of Rad51, PARP1, ATR, ATM, hMSH6, XRCC5, POLB, SKP2 to mismatch DNA damage dependent on H3K36me3, and promotes the formation of DNA damage repair complexes. [Also see and Supplemental Results: miR-26a-1 promotes the formation of DNA damage repair complex dependent on the H3K36me3 (FigureS8A-F)].

**miR-26a-1 promotes the formation of DNA damage repair complexes dependent on long non-coding RNA HULC**

In order to investigate whether miR-26a-1 promotes the formation of DNA damage repair complexes, we first analyzed whether non-coding RNA HULC is related to the formation of DNA damage repair complexes. HULC was significantly increased in the rLV-HULC group compared with the rLV group and reduced in the pGFP-V-RS-HULC group compared with the pGFP-V-RS group (Fig. 8A). The binding ability of PARP1, Rad51 to HULC was significantly enhanced in the rLV-HULC group compared with the rLV group and reduced in the pGFP-V-RS-HULC group compared with the pGFP-V-RS group (Fig. 8B). Compared with the rLV group, in the rLV-HULC group, The binding ability of H3K36me3, Rad51, PARP1, ATR, ATM, hMSH6, XRCC5, POLB, SKP2 to mismatched DNA damage probes was significantly reduced in the rLV-HULC group compared with the rLV group and enhanced in the pGFP-V-RS-HULC group compared with the pGFP-V-RS group (Fig. 8C). Compared with the rLV group, The binding ability of H3K36me3, Rad51, PARP1, ATR, ATM, hMSH6, XRCC5, POLB, SKP2 to mismatched DNA sequences was significantly weakened in the rLV-HULC group compared with the rLV group and increased in the pGFP-V-RS-HULC group compared with the pGFP-V-RS group (Fig. 8D). The mutual binding ability between PARP1, Rad51 to HULC was significantly reduced in the rLV-HULC group compared with the rLV group and increased in the
pGFP-V-RS-HULC group compared with the pGFP-V-RS group (Fig. 8E). The expression of HULC was not significantly altered in the rLV-miR-26a-1 group compared with the rLV group, however, it was significantly increased in the rLV-miR-26a-1 + rLV-HULC group (Fig. 8F). The binding capacity of H3K36me3, Rad51, PARP1, ATR, ATM, hMSH6, XRCC5, POLB, and SKP2 to mismatched DNA damage probes was significantly increased in the rLV-miR-26a-1 group compared with the rLV group, however, it was not significantly changed in the rLV-miR-26a-1 + rLV-HULC group compared with the rLV group (Fig. 8G). Compared with the rLV group, the ability of Rad51, PARP1, ATR, ATM, hMSH6, XRCC5, POLB, SKP2 to mismatched DNA sequences were significantly enhanced in the rLV-miR-26a-1 group compared with the rLV group, however, it was not significantly altered in the rLV-miR-26a-1 + rLV-HULC group compared with the rLV group (Fig. 8H). Collectively, these results suggest that miR-26a-1 promotes the formation of DNA damage repair complexes dependent on long non-coding RNA HULC in liver cancer stem cells. [Also see and Supplemental Results: miR-26a-1 promotes the formation of DNA damage repair complexes dependent on long non-coding RNA HULC (Figure S9A-C)].

**miR-26a-1 promotes DNA damage repair in human liver cancer stem cells**

Given that miR-26a-1 promotes the formation of the DNA damage repair complex, we will analyze whether miR-26a-1 affects the DNA damage repair in liver cancer stem cells. rH2AX (S139) was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group and increased in the rLV-Cas9-miR-26a-1 group compared with the rLV group (Fig. 9A). However, it was not significantly altered in the hLSCCs of the rLV-miR-26a-1 + rLV-KDM5A group compared with the rLV group (Fig. 9B). rH2AX (S139) was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group and increased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 9C). However, it was not significantly altered in the rLV-miR-26a-1 + rLV-Sirt1 group compared with the rLV group (Fig. 9D). Alisertib was used to induce cellular DNA damage, and Western blotting was used to detect the level of DNA damage marker rH2AX (S139). The results showed that the rH2AX(S139) level was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group and increased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 9E). However, it was not significantly altered in the rLV-miR-26a-1 + rLV-Sirt1 group compared with the rLV group (Fig. 9F). The mismatched DNA plasmid was transfected, and then PCR combined with BamHI-EcoRI restriction analysis was used to detect the level of DNA damage repair. The results showed that the DNA damage repair was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and decreased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 9G). After Alisertib induces cellular DNA damage, the DNA damage repair level as signficantly increased in the rLV-miR-26a-1 group compared with the rLV group and decreased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 9H). DNA microsatellite instability was significantly reduced as significantly increased in the rLV-miR-26a-1 group compared with the rLV group and increased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 9I). However, it was not significantly altered in the rLV-miR-26a-1 + rLV-KDM5A group and rLV-miR-26a-1 + rLV-Sirt1 group compared with the rLV group (Fig. 8J). The level of rH2AX (S139) was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group (31.52 ± 2.69% vs 11.93 ± 1.58%, P = 0.0026 < 0.01) and increased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group.
group ((34.01 ± 6.66% vs 77.04 ± 7.07%, P = 0.000122 < 0.01) (Fig. 9K). However, it was not significantly altered in the rLV-miR-26a-1 + rLV-KDM5A and the rLV-miR-26a-1 + rLV-Sirt1 groups compared with the rLV group (40.67 ± 1.06% vs 43.93 ± 6.61%, P = 0.23545 > 0.05; 40.67 ± 1.06% vs 37.12 ± 9.78%, P = 0.2789 > 0.05) (Fig. 9L). The degree of DNA damage was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group (1.65 ± 0.125 vs 0.21 ± 0.091, P = 0.0031253 < 0.01) and increased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (1.59 ± 0.216 vs 3.54 ± 0.35, P = 0.0009218 < 0.01) (Fig. 9Ma). Next, 8-hydroxy-deoxyguanine (8-OHdG) DNA damage analysis was performed. The results showed that the degree of DNA damage was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group (0.613 ± 0.144 vs 0.233 ± 0.115, P = 0.0035 < 0.01) in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (0.88 ± 0.65 vs 2.07 ± 0.165, P = 0.001524 < 0.01) (Fig. 9Mb). Although the degree of DNA damage was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group (2.63 ± 0.411 vs 0.45 ± 0.061, P = 0.00762 < 0.01). However, it was not significantly altered in the rLV-miR-26a-1 + rLV-KDM5A and rLV-miR-26a-1 + rLV-Sirt1 groups compared with the rLV group (2.63 ± 0.411 vs 2.26 ± 0.69, P = 0.3112 > 0.05; 2.63 ± 0.411 vs 2.27 ± 0.806, P = 0.29134 > 0.05) (Fig. 9Na). Then, 8-hydroxy-deoxyguanine (8-OHdG) DNA damage analysis was performed, and the results showed that although DNA damage was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group (0.823 ± 0.061 vs 0.427 ± 0.0404, P = 0.008298 < 0.01). However, it was not significantly altered in the rLV-miR-26a-1 + rLV-KDM5A and rLV-miR-26a-1 + rLV-Sirt1 groups compared with the rLV-Cas9 group (0.823 ± 0.061 vs 0.86 ± 0.07, P = 0.18403 > 0.05; 0.823 ± 0.061 vs 0.746 ± 0.1242, P = 0.230065 > 0.05) (Fig. 9Nb). Collectively, these results suggest that miR-26a-1 promotes the DNA damage repair by inhibiting Sirt1 and KDM5A. [Also see and Supplemental Results: miR-26a-1 promotes the DNA damage repair by inhibiting Sirt1 and KDM5A (FigureS10A-N)]

miR-26a-1 triggers the renewal of histones after the repair of DNA damage in liver cancer stem cells

Given that miR-26a-1 promotes the repair of DNA damage, we will analyze whether miR-26a-1 affects the renewal of histones after the repair of DNA damage in liver cancer stem cells. After DNA damage was induced by alisertib, the binding ability of H3F3A to Skp2, CUL1, and F-box was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 10A). The binding ability of H3F3A, Skp2, CUL1, and F-box to mismatched DNA damage probes was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 10B). The H3F3A ubiquitination modification was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 10C). The ubiquitination level of H3F3A bound by the DNA damage probe was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 10D). The H3F3A ubiquitination modification was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 10E). By transfecting mismatched plasmids, the ubiquitination level of H3F3A bound to the DNA damage probe was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-
Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 10F). After alisertib was used to induce DNA damage, H3F3A was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group and increased in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 10G). The binding ability of H3F3A to the repaired DNA sequence was significantly reduced, and the binding ability of Histone H3 to the repaired DNA sequence was significantly increased in the rLV-miR-26a-1 group compared with the rLV group and reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 10H). The above results suggest that miR-26a-1 increases the renewal ability of histones after DNA damage repair, that is, enhances the ability of H3F3A to be replaced by Histone H3. H3F3A was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group. However, it was not significantly altered in the rLV-miR-26a-1 + MG132 group compared with the rLV group (Fig. 10I). The binding ability of H3F3A to the repaired DNA sequence was significantly reduced, and the binding ability of Histone H3 to the repaired DNA sequence was significantly increased in the rLV-miR-26a-1 group compared with the rLV group. However, it was not significantly altered in the rLV-miR-26a-1 + MG132 group compared with the rLV group (Fig. 10J). Collectively, these results suggest that miR-26a-1 increases the renewal ability of histones dependent on protein ubiquitination degradation pathway after DNA damage repair.

**miR-26a-1 inhibits the expression of cyclins and protein kinase dependent on DNA damage repair in liver cancer stem cells**

Given that miR-26a-1 promotes the repair of DNA damage in liver cancer stem cells, we will consider whether miR-26a-1 inhibits the expression of cyclins and protein kinase dependent on DNA damage repair in liver cancer stem cells. The expression of CDK2, CyclinE, CDK4, CyclinD1, CDK6, CDK8, CyclinM2, CDK15, pRB, PCNA, MAP3K2, PGK1 was significantly reduced and the expression of RB, P18, P21 were significantly increased in the rLV-miR-26a-1 group compared with the rLV group. Similarly, the expression of CDK2, CyclinE, CDK4, CyclinD1, CDK6, CDK8, CyclinM2, CDK15, pRB, PCNA, MAP3K2, and PGK1 were significantly increased and the expression of RB, P18, P21/WAF1/Cip1 were significantly reduced in the rLV-Cas9-miR-26a-1 group compared with the rLV-Cas9 group (Fig. 11A). The expressions of CDK2, CyclinE, CDK4, CyclinD1, CDK6, CDK8, CyclinM2, CDK15, pRB, PCNA, MAP3K2, PGK1 were significantly reduced and the expression of RB, P18, P21/The expression of WAF1/Cip1 were significantly increased in the rLV-Cas9-miR-26a-1 group compared with the Rlv group. However, the expression of CDK2, CyclinE, CDK4, CyclinD1, CDK6, CDK8, CyclinM2, CDK15, pRB, PCNA, MAP3K2, PGK1 were not significantly changed in the rLV-miR-26a-1 + Rucaparib (DNA damage repair inhibitor) group compared with the rLV group (Fig. 11B). Collectively, these results suggest that miR-26a-1 affects the expression of cyclin and protein kinase dependent on DNA damage repair in liver cancer stem cells. **Also see and Supplemental Results:** miR-26a-1 inhibits the expression of cyclins and protein kinase dependent on DNA damage repair in liver cancer stem cells (FigureS12A-B).

**Excessive Sirt1 and KDM5A abolish the oncogenic function of miR-26a-1**
Since miR-26a-1 promotes the DNA damage repair dependent on Sirt1 and KDM5A and inhibit the growth of liver cancer stem cells *in vivo and in vitro*, we will analyze whether excessive Sirt1 and KDM5A can abolish the ability of miR-26a-1 to inhibit the growth of liver cancer stem cells. miR-26a-1-5p/3p ,miR-26a-1 precursor were significantly increased in the rLV-miR-26a-1 group, rLV-miR-26a-1 + rLV-Sirt1 group, rLV-miR-26a-1 + rLV-KDM5A group compared with the rLV group, respectively (P < 0.01) (Fig. 12A-C). The expression of Sirt1 and KDM5A were significantly reduced in the rLV-miR-26a-1 group compared with the rLV group. The expression of Sirt1 was significantly increased in the rLV-miR-26a-1 + rLV-Sirt1 group and decreased in rLV-miR-26a-1 + rLV-KDM5A group compared with the rLV group. KDM5A expression was significantly reduced in rLV-miR-26a-1 + rLV-Sirt1 group and increased in rLV-miR-26a-1 + rLV-KDM5A group compared with the rLV group (Fig. 12D). The cellular proliferation ability was significantly decreased in the rLV-miR-26a-1 group compared with the rLV group (24 hours: P = 0.0705 < 0.01; 48 hours: P = 0.0788 < 0.01). However, compared with the rLV group, it was not significantly altered in rLV-miR-26a-1 + rLV-Sirt1 group and rLV-miR-26a-1 + rLV-KDM5A group (P > 0.05) (Fig. 12E). The BrdU positive rate was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group (36.53 ± 4.69% vs 14.27 ± 2.79%, P = 0.0099 < 0.01). However, it was not significantly altered in rLV-miR-26a-1 + rLV-Sirt1 group (36.53 ± 4.69% vs 32.01 ± 8.18%, P = 0.085 > 0.05) and the rLV-miR-26a-1 + rLV-KDM5A group (36.53 ± 4.69% vs 31.672.11%, P = < 0.01) (Fig. 12F). The colony formation rate was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group (62.38 ± 4.503% vs 27.92 ± 3.79%, P = 0.0094 < 0.01). However, it was not significantly altered in rLV-miR-26a-1 + rLV-Sirt1 group (62.38 ± 4.503% vs 59.41 ± 5.46%, P = 0.2308 > 0.05) and the rLV-miR-26a-1 + rLV-KDM5A group (62.38 ± 4.503% vs 55.73 ± 7.874%, P = 0.1224 > 0.05) (Fig. 12G). The sphere formation rate was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group (83.78 ± 7.05% vs 37.99 ± 4.62%, P = 0.00768 < 0.01). However, it was not significantly altered in rLV-miR-26a-1 + rLV-Sirt1 group (83.78 ± 7.05% vs 80.08 ± 8.95%, P = 0.30768 > 0.05) and the rLV-miR-26a-1 + rLV-KDM5A group (83.78 ± 7.05% vs 80.08 ± 8.95%, P = 0.3601 > 0.05) (Fig. 12H). The average weight of transplanted tumors was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group (0.92 ± 0.12 g vs 0.32 ± 0.069 g, P = 0.000000074 < 0.01). However, it was not significantly altered in rLV-miR-26a-1 + rLV-Sirt1 group (0.92 ± 0.12 g vs 0.81 ± 0.16g, P = 0.0732 > 0.05) and rLV-miR-26a-1 + rLV-KDM5A group (0.92 ± 0.12g vs 0.79 ± 0.23g, P = 0.062 > 0.05) (Fig. 12I-J). The average xenograft appearance time was significantly increased in the rLV-miR-26a-1 group compared with the rLV group (8.19 ± 1.401 days vs 13.27 ± 3.47 days, P = 0.000123 < 0.01). However, it was not significantly altered in rLV-miR-26a-1 + rLV-Sirt1 group (8.19 ± 1.401 days vs 8.36 ± 1.43 days, P = 0.393975 > 0.05) and the rLV-miR-26a-1 + rLV-KDM5A group (8.19 ± 1.401 days vs 8.72 ± 2.57 days, P = 0.2466 > 0.05) (Fig. 12K). The poorly differentiated tumor cells was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group. However, it was not significantly altered in the rLV-miR-26a-1 + rLV-Sirt1 group and rLV-miR-26a-1 + rLV-KDM5A group (Fig. 12L). The positive rate of PCNA was significantly reduced in the rLV-miR-26a-1 group compared with the rLV group (65.19 ± 11.89% vs 65.19 ± 11.89%, P = 0.0000001068 < 0.01) However, it was not significantly altered in the rLV-miR-26a-1 + rLV-Sirt1 group (65.19 ± 11.89% vs 59.94 ± 10.22%, P = 0.1015 > 0.05) and in the rLV-miR-26a-1 + rLV-KDM5A group (65.19 ± 11.89% vs. 62.203 ± 7.812%, P = 0.207 > 0.05) (Fig. 12M&N). Collectively, these results suggest that Sirt and KDM5A overdose abolish the ability of miR-26-1 to reduce the growth of liver cancer
stem cells. [Also see and Supplemental Results: Excessive Sirt1 and KDM5A abolish miR-26a-1's ability to inhibit the growth of liver cancer stem cells (FigureS13A-N)].

**Discussion**

In this study, our results suggest that miR-26a-1 inhibits the NAD(+)–dependent deacetylase Sirt1 expression by targeting the 3' non-coding region of Sirt1 which enhances the acetylation modification of histone H4 on the 16th lysine and the expression of protein arginine methyltransferase PRMT6. Therefore, miR-26a-1 promotes arginine methylation modification of POLB (R137) and Histone. On the other hand, miR-26a-1 inhibits the expression of KDM5A by targeting its 3' non-coding region, which enhances the methylation modification of histone H3 lysine 4. Moreover, miR-26a-1 enhances the expression of histone methyltransferase SETD2 dependent on H3K4me3 and further increases the trimethylation modification of the histone H3 lysine 36. Significantly, miR-26a-1 promotes the formation of DNA damage repair complex (Rad51-PARP1-ATR-ATM-hMSH6-XRCC-POLB-SKP2) via H3K36me3. In particular, it was found that miR-26a-1 inhibited the function of long non-coding RNA HULC and promoted the formation of DNA damage repair complex. Furthermore, miR-26a-1 promotes the DNA damage repair ability by promoting the DNA damage repair complex to bind to the DNA damage site, thereby inhibiting the DNA damage of liver cancer stem cells. In particular, miR-26a-1 enhanced the binding of H3F3A to Skp2, CUL1, and F-box at the DNA damage site and enhanced the protein ubiquitination modification of H3F3A, which promoted the Histone H3 replacing H3F3A, realizing the renewal of histones after DNA damage repair. It was further found that miR-26a-1 inhibited the formation and instability of DNA microsatellites by promoting DNA damage repair, thereby affecting the expression of several cyclins and protein kinases in liver cancer stem cells, such as, inhibiting CDK2 and CyclinE, CDK4, CyclinD1, CDK6, CDK8, CyclinM2, CDK15, pRB, PCNA, MAP3K2, PGK1 and promoting RB, P18, P21/WAF1/Cip1, and thus inhibited the growth of liver cancer stem cells in vivo and in vitro (Fig. 13).

Notably, our results suggest that miR-26a-1 inhibits the growth of human liver cancer stem cells, and excessive Sirt and KDM5A abrogated the oncogenic functions of miR-26-1. Moreover, our results suggest miR-26a-1 targets NAD+-dependent deacetylase Sirt1 and enhances the acetylation modification of histone H4 lysine 16. Sirtuin-1 (SIRT1) is a class-III histone deacetylase (HDAC), an NAD+-dependent enzyme deeply involved in gene regulation, genome stability maintenance, apoptosis, autophagy, senescence, proliferation and tumorigenesis. It also has a key role in the epigenetic regulation of tissue homeostasis and many diseases by deacetylating both histone and non-histone target (11–13). Accumulating evidence has indicated that SIRT1 is a key regulator of DNA damage and cancer(14, 15).

Intriguingly, our results suggest that miR-26a-1 enhances the expression of protein arginine methyltransferase PRMT6 gene dependente on H4K16Ac. Protein methyltransferase 6 (PRMT6) to be frequently downregulated in hepatocellular carcinoma (HCC) and regulates RAS/RAF through CRAF methylation(16). PPARα protects against colon carcinogenesis via regulation of PRMT6(17). PTEN arginine methylation by PRMT6 suppresses PI3K-AKT signaling (18). CRAF methylation by PRMT6 regulates hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation(19).
Furthermore, our results suggest that miR-26a-1 enhances the methylation modification of POLB(R137) and histone arginine through PRMT6. Nuclear DNA repair polymerase, POLB, is located in the mitochondria and plays a significant role in mitochondrial BER, mtDNA integrity and mitochondrial function (20). Genome instability caused by a germline mutation in the human DNA repair gene POLB (21).

Interestingly, our results suggest that miR-26a-1 enhances the methylation modification of histone H3 lysine 4 by reducing KDM5A. KDM5A acts as a negative regulator of p53 signaling (22). KDM5A bound directly to MPC-1 promoter region and suppressed the expression (23). KDM5A/5B knockdown resulted in lower viability of HL-60 cells (24). KDM5A acts as a critical editor of the cells' "histone code" that is required to recruit DNA repair complexes to DNA breaks (25). HDAC1 negatively regulates selective mitotic chromatin in a KDM5A-dependent manner (26). Amplification of KDM5A is observed in many cancers, including breast cancer, prostate cancer, hepatocellular carcinoma (27). The H3K4 tri-demethylase KDM5A and specific COMPASS/KMT2 H3K4 methyltransferases modulate different TSSG loci through H3K4 methylation states and KDM4A recruitment (28).

The initiation and transduction of DNA damage response (DDR) occur in the context of chromatin. JMJD6 modulates DNA damage response through downregulating H4K16Ac (29). MDM2-MOF-H4K16Ac axis contributes to tumorigenesis induced by Notch (30). Trimethylation of histone H3 at lysine 4 (H3K4me3) breadth is linked to cell identity and transcriptional consistency (31). NEK2 promotes tumor growth of gastric cancer cells via regulating KDM5B/H3K4me3 (32). SMYD3 promotes metastasis of ovarian cancer via H3K4 me3 (33).

In particular, our results suggest that miR-26a-1 enhances the expression of histone methyltransferase SETD2 and the trimethylation modification on the 36th lysine of Histone H3 dependent on H3K4me3. Loss of SETD2 (the sole histone H3K36 tri-methyltransferase) promotes K-ras-induced carcinogenesis (34). SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways (35). SETD2 regulates osteosarcoma cell growth by suppressing Wnt/β-catenin signaling (36). The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα (37, 38).

Strikingly, our results suggest that miR-26a-1 enhances the binding ability of Rad51, PARP1, ATR, ATM, hMSH6, XRCC5, POLB, SKP2 to mismatch DNA damage dependent on H3K36me3, and promotes the formation of DNA damage repair complexes. RAD51 promotes homology-directed repair (HDR), replication fork reversal, and stalled fork protection (39). PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers (40). The ATM, ATR, DNA-PK family proteins can be activated immediately upon DNA damage recognition (41). The phosphorylation of hMSH6 is involved in cellular signaling of either DNA mismatch repair or MMR-dependent damage recognition activities (43). The hMsh2-hMsh6 complex acts in concert with monoubiquitinated PCNA and Pol η in response to oxidative DNA damage in human cells (44). The XRCC genes results in their roles in DNA repair and genetic stability (45). SKP2 promotes tumorigenesis and radiation tolerance through PDCD4 ubiquitination (46).
Also, our results suggest that miR-26a-1 promotes the formation of DNA damage repair complexes dependent on long non-coding RNA HULC in liver cancer stem cells. As an oncogene, HULC promotes tumorigenesis by regulating multiple pathways, such as down-regulation of EEF1E1 (47). LncRNA HULC triggers autophagy via stabilizing Sirt1 (48). Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer (49).

In particular, our results suggest that miR-26a-1 promotes the DNA damage repair by inhibiting Sirt1 and KDM5A. On the other hand, our results suggest that miR-26a-1 increases the renewal ability of histones dependent on protein ubiquitination degradation pathway after DNA damage repair. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone (50). Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone (51). H3F3A promotes lung cancer cell migration through intronic regulation (52). CUL1 is an essential component of SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex, and promotes breast cancer metastasis through regulating EZH2 (53). F-box proteins have pivotal roles in multiple cellular processes through ubiquitylation and subsequent degradation of target proteins (54).

Ultimately, our results suggest that miR-26a-1 affects the expression of cyclin and protein kinase dependent on DNA damage repair in liver cancer stem cells. CDK2 positively regulates aerobic glycolysis by suppressing SIRT5 in gastric cancer (55). MAP kinase dependent cyclinE/CDK2 activity promotes DNA replication (56, 57). p21CIP1 promotes cancer-initiating cells via activation of Wnt/TCF1/CyclinD1 signaling (58). CDK8 promotes angiogenesis in pancreatic cancer via activation of the CDK8-β-catenin-KLF2 signaling axis (59). Recent studies suggest CNNM2 (cyclin M2) to be part of the long-sought basolateral Mg2+ extruder at the renal distal convoluted tubule (60). PA28α/β promotes breast cancer cell invasion and metastasis via down-regulation of CDK15 (61). Retinoblastoma protein (pRB) pathway plays a significant role in the development of most human cancers. Loss of pRB results in deregulated cell proliferation and apoptosis (62). Proliferating cell nuclear antigen (PCNA) is known as a molecular marker for proliferation (63). methylation of MAP3K2 by SMYD3 increases MAP kinase signalling and promotes the formation of Ras-driven carcinomas (64). Phosphoglycerate kinase 1 (PGK1) is an important enzyme in the metabolic glycolysis pathway and the acetylation of PGK1 promotes tumorigenesis (65). p18 blocks reprogramming by targeting Cdk4/6-mediated cell cycle regulation (66). Tumor suppressor p21(Waf1/Cip1) functions as a link from p53 to cell-cycle arrest and DNA repair (67).

In conclusions, miR-26a-1 inhibits the expression of NAD+-dependent deacetylase Sirt1 and KDM5A, thereafter, miR-26a-1 promotes DNA damage repair, thereby affecting the expression of some cyclins and protein kinases in liver cancer stem cells. Moreover, excessive Sirt1 and KDM5A abolished miR-26a-1’s ability to inhibit the growth of liver cancer stem cells. miR26a-1 may acts as the potential biomarker and therapeutic target for liver cancer. We also shed light on the fact that the attenuation of deregulated functioning of miRNA could be a viable approach for cancer treatment.

Conclusions
miR-26a-1 inhibits the expression of NAD+-dependent deacetylase Sirt1 and KDM5A, thereafter, miR-26a-1 promotes DNA damage repair, thereby affecting the expression of some cyclins and protein kinases in liver cancer stem cells. Moreover, excessive Sirt1 and KDM5A abolished miR-26a-1's ability to inhibit the growth of liver cancer stem cells. miR26a-1 may acts as the potential biomarker and therapeutic target for liver cancer. We also shed light on the fact that the attenuation of deregulated functioning of miRNA could be a viable approach for cancer treatment.

**List Of Abbreviations**

RNA G-quadruplexes (RG4s)

sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)

RNA Immunoprecipitation(RIP)

3'-uncoding region (UTR)

class-III histone deacetylase (HDAC)

Protein methyltransferase 6 (PRMT6)

**Declarations**

**Ethics approval and consent to participate**

All methods were carried out in "accordance" with the approved guidelines. All experimental protocols "were approved by" a Tongji university institutional committee. Informed consent was obtained from all subjects. The study was reviewed and approved by the China national institutional animal care and use committee.

**Consent for publication**

'Not applicable'

**Availability of data and material**

'Not applicable'

**Competing interests**

"The authors declare that they have no competing interests"

**Authors' contributions**
Dongdong Lu conceived the study and participated in the study design, performance, coordination and manuscript writing. Liyan Wang, Xiaonan Li, Rushi Qin, Yanan Lu, Shuting Song, Yingjie Chen, Sijie Xie, Xiaoxue Jiang performed the research. All authors have read and approved the final manuscript.

Acknowledgements

This study was supported by grants from National Natural Science Fundation of China (NCSF No.8127229181773158 and NCSF No.82073130) and by grants from Science and Technology Commission of Shanghai Municipality Shanghai Science and Technology Plan Basic Research Field Project 20JC1411400 and by grants from Science and Technology Commission of Shanghai Municipality Shanghai Science and Technology Plan Basic Research Field Project 19JC1415200.

References

1. Acharya A, Berry DC, Zhang H, Jiang Y, Jones BT, Hammer RE, Graff JM, Mendell JT. miR-26 suppresses adipocyte progenitor differentiation and fat production by targeting Fbxl19. Genes Dev. 2019;33(19-20):1367-1380
2. RNA G-quadruplex regulates microRNA-26a biogenesis and function. Liu G, Du W, Xu H, Sun Q, Tang D, Zou S, Zhang Y, Ma M, Zhang G, Du X, Ju S, Cheng W, Tian Y, Fu X. RNA G-quadruplex regulates microRNA-26a biogenesis and function. J Hepatol. 2020;73(2):371-382
3. Peng J, He X, Zhang L, Liu P. MicroRNA-26a protects vascular smooth muscle cells against H2O2-induced injury through activation of the PTEN/AKT/mTOR pathway. Int J Mol Med. 2018 Sep;42(3):1367-1378
4. Sun YF, Kan Q, Yang Y, Zhang YH, Shen JX, Zhang C, Zhou XY. Knockout of microRNA-26a promotes lung development and pulmonary surfactant synthesis. Mol Med Rep. 2018 Apr;17(4):5988-5995
5. Sekimoto N, Suzuki A, Suzuki Y, Sugano S. Expression of miR-26a exhibits a negative correlation with HMGA1 and regulates cancer progression by targeting HMGA1 in lung adenocarcinoma cells. Mol Med Rep. 2017;15(2):534-542
6. DNA damage and the balance between survival and death in cancer biology. Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer. 2016 Jan;16(1):20-33
7. Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen. 2017;58(5):235-263
8. Uckelmann M, Sixma TK. Histone ubiquitination in the DNA damage response. DNA Repair (Amst). 2017;56:92-101
9. Hosoya N, Miyagawa K. Targeting DNA damage response in cancer therapy. Cancer Sci. 2014;105(4):370-88
10. Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol. 2013;754:3-29.
11. The Role of SIRT1 on DNA Damage Response and Epigenetic Alterations in Cancer. Alves-Fernandes DK, Jasiulionis MG. The Role of SIRT1 on DNA Damage Response and Epigenetic Alterations in Cancer. Int J Mol Sci. 2019;20(13):3153

12. Imperatore F, Maurizio J, Vargas Aguilar S, Busch CJ, Favret J, Kowenz-Leutz E, Cathou W, Gentek R, Perrin P, Leutz A, Berruyer C, Sieweke MH. SIRT1 regulates macrophage self-renewal. EMBO J. 2017;36(16):2353-2372

13. Karbasforooshan H, Roohbakhsh A, Karimi G. SIRT1 and microRNAs: The role in breast, lung and prostate cancers. Exp Cell Res. 2018;367(1):1-6

14. Yang H, Bi Y, Xue L, Wang J, Lu Y, Zhang Z, Chen X, Chu Y, Yang R, Wang R, Liu G. Multifaceted Modulation of SIRT1 in Cancer and Inflammation. Crit Rev Oncog. 2015;20(1-2):49-64

15. Zhao B, Li X, Zhou L, Wang Y, Shang P. SIRT1: a potential tumour biomarker and therapeutic target. J Drug Target. 2019;27(10):1046-1052

16. Chan LH, Zhou L, Ng KY, Wong TL, Lee TK, Sharma R, Loong JH, Ching YP, Yuan YF, Xie D, Lo CM, Man K, Artegiani B, Cleverson H, Yan HH, Leung SY, Richard S, Guan XY, Huen MSY, Ma S. PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation. Cell Rep. 2018;25(3):690-701

17. Luo Y, Xie C, Brocker CN, Fan J, Wu X, Feng L, Wang Q, Zhao J, Lu D, Tandon M, Cam M, Krausz KW, Liu W, Gonzalez FJ. Intestinal PPARα Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6. Gastroenterology. 2019;157(3):744-759

18. Feng J, Dang Y, Zhang W, Zhao X, Zhang C, Hou Z, Jin Y, McNutt MA, Marks AR, Yin Y. PTEN arginine methylation by PRMT6 suppresses PI3K-AKT signaling and modulates pre-mRNA splicing. Proc Natl Acad Sci U S A. 2019;116(14):6868-6877

19. Wong TL, Ng KY, Tan KV, Chan LH, Zhou L, Che N, Hoo RLC, Lee TK, Richard S, Lo CM, Man K, Khong PL, Ma S. CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation. Hepatology. 2020;71(4):1279-1296

20. Kaufman BA, Van Houten B. POLB: A new role of DNA polymerase beta in mitochondrial base excision repair. DNA Repair (Amst). 2017 Dec;60:A1-A5

21. Sobol RW. Genome instability caused by a germline mutation in the human DNA repair gene POLB. PLoS Genet. 2012;8(11):e1003086

22. KDM5A regulates a translational program that controls p53 protein expression. Hu D, Jablonowski C, Cheng PH, AlTahan A, Li C, Wang Y, Palmer L, Lan C, Sun B, Abu-Zaid A, Fan Y, Brimble M, Gamboa NT, Kumbhar RC, Yanishhevski D, Miller KM, Kang G, Zambetti GP, Chen T, Yan Q, Davidoff AM, Yang J. KDM5A Regulates a Translational Program that Controls p53 Protein Expression. iScience. 2018;9:84-100

23. Cui J, Quan M, Xie D, Gao Y, Guha S, Fallon MB, Chen J, Xie K. A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism. Oncogene. 2020 Jan;39(5):1140-1151
24. Shokri G, Doudi S, Fathi-Roudsari M, Kouhkan F, Sanati MH. Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view. Leuk Res. 2018;68:105-111

25. Price BD. KDM5A demethylase: Erasing histone modifications to promote repair of DNA breaks. J Cell Biol. 2017 Jul 3;216(7):1871-1873

26. Dreval K, Lake RJ, Fan HY. HDAC1 negatively regulates selective mitotic chromatin binding of the Notch effector RBPJ in a KDM5A-dependent manner. Nucleic Acids Res. 2019;47(9):4521-4538

27. Petronikolou N, Longbotham JE, Fujimori DG. Extended Recognition of the Histone H3 Tail by Histone Demethylase KDM5A. Biochemistry. 2020;59(5):647-651

28. Mishra S, Van Rechem C, Pal S, Clarke TL, Chakraborty D, Mahan SD, Black JC, Murphy SE, Lawrence MS, Daniels DL, Whetstine JR. Cross-talk between Lysine-Modifying Enzymes Controls Site-Specific DNA Amplifications. Cell. 2018;174(4):803-817.e16

29. Huo D, Chen H, Cheng Y, Song X, Zhang K, Li MJ, Xuan C. JMJD6 modulates DNA damage response through downregulating H4K16ac independently of its enzymatic activity. Cell Death Differ. 2020;27(3):1052-1066

30. Liu Y, Xing ZB, Wang SQ, Chen S, Liu YK, Li YH, Li YF, Wang YQ, Lu Y, Hu WN, Zhang JH. MDM2-MOF-H4K16ac axis contributes to tumorigenesis induced by Notch. FEBS J. 2014;281(15):3315-24

31. Benayoun BA, Pollina EA, Ucar D, Mahmoudi S, Karra K, Wong ED, Devarajan K, Daugherty AC, Kundaje AB, Mancini E, Hitz BC, Gupta R, Rando TA, Baker JC, Snyder MP, Cherry JM, Brunet A. H3K4me3 breadth is linked to cell identity and transcriptional consistency. Cell. 2014;158(3):673-88

32. Li Y, Chen L, Feng L, Zhu M, Shen Q, Fang Y, Liu X, Zhang X. NEK2 promotes proliferation, migration and tumor growth of gastric cancer cells via regulating KDM5B/H3K4me3. Am J Cancer Res. 2019;9(11):2364-2378

33. Lyu T, Jiang Y, Jia N, Che X, Li Q, Yu Y, Hua K, Bast RC Jr, Feng W. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters. Int J Cancer. 2020;146(6):1553-1567

34. Niu N, Lu P, Yang Y, He R, Zhang L, Shi J, Wu J, Yang M, Zhang ZG, Wang LW, Gao WQ, Habtezion A, Xiao GG, Sun Y, Li L, Xue J. Gut. 2020;69(4):715-726

35. Yuan H, Han Y, Wang X, Li N, Liu Q, Yin Y, Wang H, Pan L, Li L, Song K, Qiu T, Pan Q, Chen Q, Zhang G, Zang Y, Tan M, Zhang J, Li Q, Wang X, Jiang J, Qin J. SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways. Cancer Cell. 2020:S1535-6108(20)30272-5

36. Jiang C, He C, Wu Z, Li F, Xiao J. Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/β-catenin signaling. Biochem Biophys Res Commun. 2018;502(3):382-388

37. Fang J, Huang Y, Mao G, Yang S, Rennert G, Gu L, Li H, Li GM. Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3-MutSα interaction. Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):9598-9603
38. Li F, Mao G, Tong D, Huang J, Gu L, Yang W, Li GM. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα. Cell. 2013;153(3):590-600.

39. Dungrawala H, Bhat KP, Le Meur R, Chazin WJ, Ding X, Sharan SK, Wessel SR, Sathe AA, Zhao R, Cortez D. RAD51 Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks. Mol Cell. 2017;67(3):374-386.

40. Ali R, Alabdullah M, Alblihy A, Miligy I, Mesquita KA, Chan SY, Moseley P, Rakha EA, Madhusudan S. PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. Cancer Lett. 2020;469:124-133.

41. Ma M, Rodriguez A, Sugimoto K. Activation of ATR-related protein kinase upon DNA damage recognition. Curr Genet. 2020 Apr;66(2):327-333.

42. Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacol Ther. 2015;149:124-38.

43. Kaliyaperumal S, Patrick SM, Williams KJ. Phosphorylated hMSH6: DNA mismatch versus DNA damage recognition. Mutat Res. 2011;706(1-2):36-45T.

44. Zlatanou A, Despras E, Braz-Petta T, Boubakour-Azzouz I, Pouvelle C, Stewart GS, Nakajima S, Yasui A, Ishchenko AA, Kannouche PL. The hMsh2-hMsh6 complex acts in concert with monoubiquitinated PCNA and Pol η in response to oxidative DNA damage in human cells. Mol Cell. 2011;43(4):649-62.

45. Thacker J, Zdzienicka MZ. The mammalian XRCC genes: their roles in DNA repair and genetic stability. DNA Repair (Amst). 2003;2(6):655-72.

46. Li C, Du L, Ren Y, Liu X, Jiao Q, Cui D, Wen M, Wang C, Wei G, Wang Y, Ji A, Wang Q. SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination. J Exp Clin Cancer Res. 2019;38(1):76.

47. Yu X, Zheng H, Chan MT, Wu WK. HULC: an oncogenic long non-coding RNA in human cancer. J Cell Mol Med. 2017 Feb;21(2):410-417.

48. Xiong H, Ni Z, He J, Jiang S, Li X, He J, Gong W, Zheng L, Chen S, Li B, Zhang N, Lyu X, Huang G, Chen B, Zhang Y, He F. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. 2017;36(25):3528-3540.

49. Takahashi K, Ota Y, Kogure T, Suzuki Y, Iwamoto H, Yamakita K, Kitano Y, Fujii S, Haneda M, Patel T, Ota T. Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer. Cancer Sci. 2020 Jan;111(1):98-111.

50. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goodie V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Myklebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, Amay MF, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45(12):1479-82.

51. Yoshida KI, Nakano Y, Honda-Kitahara M, Wakai S, Motoi T, Ogura K, Sano N, Shibata T, Okuma T, Iwata S, Kawai A, Ichimura K, Yoshida A. Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone. Mod Pathol. 2019;32(12):1751-1761.
52. Park SM, Choi EY, Bae M, Kim S, Park JB, Yoo H, Choi JK, Kim YJ, Lee SH, Kim IH. Histone variant H3F3A promotes lung cancer cell migration through intronic regulation. Nat Commun. 2016;7:12914

53. Huang YF, Zhang Z, Zhang M, Chen YS, Song J, Hou PF, Yong HM, Zheng JN, Bai J. CUL1 promotes breast cancer metastasis through regulating EZH2-induced the autocrine expression of the cytokines CXCL8 and IL11. Cell Death Dis. 2018;10(1):2

54. Wang Z, Liu P, Inuzuka H, Wei W. Roles of F-boxproteins in cancer. Nat Rev Cancer. 2014;14(4):233-47

55. Tang Z, Li L, Tang Y, Xie D, Wu K, Wei W, Xiao Q. CDK2 positively regulates aerobic glycolysis by suppressing SIRT5 in gastric cancer. Cancer Sci. 2018;109(8):2590-2598

56. Kisielewska J, Philipova R, Huang JY, Whitaker M. MAP kinase dependent cyclinE/cdk2 activity promotes DNA replication in early sea urchin embryos. Dev Biol. 2009;334(2):383-94

57. Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends Cell Biol. 2018;28(11):911-925

58. Benard O, Qian X, Liang H, Ren Z, Suyama K, Norton L, Hazan RB. p21CIP1 Promotes Mammary Cancer-Initiating Cells via Activation of Wnt/TCF1/CyclinD1 Signaling. Mol Cancer Res. 2019;17(7):1571-1581

59. Wei R, Kong L, Xiao Y, Yuan H, Song Y, Wang J, Yu H, Mao S, Xu W. CDK8 regulates the angiogenesis of pancreatic cancer cells in part via the CDK8-β-catenin-KLF2 signal axis. Exp Cell Res. 2018;369(2):304-315

60. Corral-Rodríguez MÁ, Stuiver M, Abascal-Palacios G, Diercks T, Oyenarte I, Ereño-Orbea J, de Opakua Al, Blanco FJ, Encinar JA, Spiwok V, Terashima H, Accardi A, Müller D, Martínez-Cruz LA. Nucleotide binding triggers a conformational change of the CBS module of the magnesium transporterCNNM2from a twisted towards a flat structure. Biochem J. 2014;464(1):23-34

61. Li S, Dai X, Gong K, Song K, Tai F, Shi J. PA28α/β Promote Breast Cancer Cell Invasion and Metastasis via Down-Regulation of CDK15. Front Oncol. 2019;9:1283

62. Hickman ES, Moroni MC, Helin K. The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev. 2002;12(1):60-6

63. Wang SC. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 2014;35(4):178-86

64. Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D, Tummino PJ, Kruger RG, Garcia BA, Butte AJ, Vermeulen M, Sage J, Gozani O. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature. 2014;510(7504):283-7

65. Hu H, Zhu W, Qin J, Chen M, Gong L, Li L, Liu X, Tao Y, Yin H, Zhou H, Zhou L, Ye D, Ye Q, Gao D. Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis. Hepatology. 2017;65(2):515-528

66. Zhu S, Cao J, Sun H, Liu K, Li Y, Zhao T. p18inhibits reprogramming through inactivation of Cdk4/6. Sci Rep. 2016;6:31085
67. Yang W, Qi Q, Zhang H, Xu W, Chen Z, Wang L, Wang Y, Dong X, Jiao H, Huo Z.
p21Waf1/Cip1 polymorphisms and risk of esophageal cancer. Ann Surg Oncol. 2010;17(5):1453-8)